Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.

Background: Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the developme...

Descripción completa

Detalles Bibliográficos
Publicado en:Breast Cancer Research Vol. 22; no. 1; pp. 1 - 19
Autores principales: Baker, Laura A., Holliday, Holly, Roden, Daniel, Krisp, Christoph, Wu, Sunny Z., Junankar, Simon, Serandour, Aurelien A., Mohammed, Hisham, Nair, Radhika, Sankaranarayanan, Geetha, Law, Andrew M. K., McFarland, Andrea, Simpson, Peter T., Lakhani, Sunil, Dodson, Eoin, Selinger, Christina, Anderson, Lyndal, Samimi, Goli, Hacker, Neville F., Lim, Elgene
Formato: research Journal Article
Publicado: BioMed Central 6/11/2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143724872&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 143724872
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14655411
        8UYJ
      jtl: Breast Cancer Research
      issn: 14655411
      maglogo: N
    pubinfo:
      dt: 6/11/2020
      vid: 22
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        143724872
        143724872
        NLM32527287
        143724872
        10.1186/s13058-020-01306-6
        NLM32527287
        143724872
      ppf: 1
      ppct: 18
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
      aug:
        au:
          Baker, Laura A.
          Holliday, Holly
          Roden, Daniel
          Krisp, Christoph
          Wu, Sunny Z.
          Junankar, Simon
          Serandour, Aurelien A.
          Mohammed, Hisham
          Nair, Radhika
          Sankaranarayanan, Geetha
          Law, Andrew M. K.
          McFarland, Andrea
          Simpson, Peter T.
          Lakhani, Sunil
          Dodson, Eoin
          Selinger, Christina
          Anderson, Lyndal
          Samimi, Goli
          Hacker, Neville F.
          Lim, Elgene
        affil: The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, 2010, Darlinghurst, NSW, Australia
      sug:
        subj:
          Proteins
          Breast Neoplasms
          Carcinoma, Basal Cell
          Carcinoma, Basal Cell Metabolism
          Breast Neoplasms Metabolism
          Proteins Metabolism
          Cell Physiology Physiology
          Carcinoma, Basal Cell Pathology
          Human
          Breast Neoplasms Pathology
          Cell Differentiation Physiology
          Tumor Cells, Cultured
          Chromosomes Metabolism
          Prognosis
          Female
          Mice
          Cell Line, Tumor
          Apoptosis Physiology
          Animal Studies
          Xenografts
          DNA
          Chromosomes
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Coping Health Inventory for Parents
          Scales
          Female
      ab: Background: Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms.Methods: Here, we have defined unique molecular insights into the function of ID4 in BLBC and the related disease high-grade serous ovarian cancer (HGSOC), by combining RIME proteomic analysis, ChIP-seq mapping of genomic binding sites and RNA-seq.Results: These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (γH2AX and BRCA1) at fragile chromatin sites. ID4 does not affect transcription at these sites, instead binding to chromatin following DNA damage. Analysis of clinical samples demonstrates that ID4 is amplified and overexpressed at a higher frequency in BRCA1-mutant BLBC compared with sporadic BLBC, providing genetic evidence for an interaction between ID4 and DNA damage repair deficiency.Conclusions: These data link the interactions of ID4 with MDC1 to DNA damage repair in the aetiology of BLBC and HGSOC.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N